Navigation Links
ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender

ST. LOUIS, Sept. 24 /PRNewswire/ -- ISTO Technologies Inc., a privately held orthobiologics company, today announced that the United States Food and Drug Administration has granted 510(k) clearance for InQu(TM). InQu is indicated for use as a bone graft extender in the spine and as a bone graft substitute in the extremities and pelvis.

InQu represents a new class of synthetic biomaterial scaffold designed to optimize structural and biological properties to support bone cell growth. InQu is a biopolymer composite of hyaluronic acid which is entangled within the three-dimensional backbone created by synthetic polyester. Hyaluronic acid, a ubiquitous component of natural tissue, is known to play a predominant role in tissue morphogenesis, cell migration, adhesion, and cell differentiation. Mitchell Seyedin, President and CEO of ISTO said, "We are very pleased to receive FDA clearance and will focus on demonstrating InQu's clinical benefit to the surgeons and patients."

More than 1 million bone grafting procedures are performed in the United States annually, and more than 3 million procedures are performed worldwide. Synthetic bone graft material represents the fastest growing segment of the orthobiologics market. "We are very excited to participate in this evolving market with our exceptional product," adds Seyedin. ISTO intends to launch InQu at the upcoming annual North American Spine Society conference in Austin, Texas.

In addition to its biomaterial platform technology, ISTO is also developing cartilage regeneration products centered on its patented cell-based technology. Cartilage regeneration is often called the "holy grail" of the orthopedic industry because of its potential to restore function to damaged joints that otherwise have limited healing potential. Cartilage serves as a "shock absorber" protecting all joints, including spinal discs, from the wear and tear experienced during motion. ISTO's first cartilage product is currently in clinical trials.

About ISTO

ISTO Technologies, Inc. is a clinical-stage orthobiologics company focused on developing differentiated products for sports medicine, spinal therapy, and trauma. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at

SOURCE ISTO Technologies Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers Develop Technologies to Devour Food Pathogens
2. Researchers Study Safety of Assisted Reproductive Technologies
3. India to Propose Global Fund for Clean Energy Technologies
4. Infant receives first bloodless liver transplant
5. British MPs Say Prostate Cancer Receives Low Priority in the NHS
6. Fifth US Patient Receives Artificial Heart
7. Northfield Labs Receives FDA Comments
8. Abbott Receives CE Mark Certification
9. Zactima Receives Fast Track Designation By The FDA
10. East London Receives World Class New Private Hospital Facility
11. Brinda Karat Receives Legal Notice over Ramdev Issue
Post Your Comments:
(Date:11/30/2015)... ... 30, 2015 , ... ChiliPad , Chili Technology’s temperature-controlled ... through quality sleep. Tim DiFrancesco, training coach for the LA Lakers, recommends ChiliPad ... precisely regulates the surface temperature of each side of the bed so that ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... patient centered orthopedic care. Led by John Vitolo, M.D., the center offers ... condition, the team at Advocare Orthopedic & Sports Medicine is ready to help ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies ... locations, patients can visit Dr. Margulies to experience the best available orthodontic experience in ... title of "NJ Top Dentist"! , Orthodontics is the branch of dentistry that specializes ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed and approved “NJ Top Dentist”, ... Tufts School of Dental Medicine in 1935. His father graduated from NYU School ... in dentistry as well as their commitment and passion to the Practice of Dentistry. ...
(Date:11/30/2015)... ... November 30, 2015 , ... The recently ... Poison Data System (NPDS) reveals that in 2014, someone called a poison center ... two million of which were human exposure cases. , The American Association of ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... India , November 30, 2015 ... 2014, and is expected to grow at a CAGR of 7.6% ... was valued at USD 135.6 million in 2014, and is ... 2020. --> According to the new Market Research Report ... invasive, non-invasive), By End User (Hospitals, ambulatory care, others) - Analysis ...
(Date:11/30/2015)... PUNE, India , November 30, 2015 ... new market research report "Dental Lasers Market by Product (Soft ... Treatment, Periodontitis), End User (Hospitals, Clinics), and Geography - Global ... USD 224.7 Million by 2020, at a CAGR of 5.2% ... , Browse 140 market data Tables and 62 Figures spread ...
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
Breaking Medicine Technology: